Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 317

1.

Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma.

Pisanu ME, Maugeri-Saccà M, Fattore L, Bruschini S, De Vitis C, Tabbì E, Bellei B, Migliano E, Kovacs D, Camera E, Picardo M, Jakopin Z, Cippitelli C, Bartolazzi A, Raffa S, Torrisi MR, Fulciniti F, Ascierto PA, Ciliberto G, Mancini R.

J Exp Clin Cancer Res. 2018 Dec 17;37(1):318. doi: 10.1186/s13046-018-0989-7.

PMID:
30558661
2.

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.

Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, Fox BA, Ascierto PA.

Oncoimmunology. 2018 Sep 5;7(12):e1405206. doi: 10.1080/2162402X.2017.1405206. eCollection 2018.

PMID:
30524879
3.

The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma.

Fattore L, Mancini R, Ascierto PA, Ciliberto G.

Expert Opin Ther Targets. 2019 Jan;23(1):53-68. doi: 10.1080/14728222.2019.1554057. Epub 2018 Dec 9.

PMID:
30507327
4.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.

JAMA Oncol. 2018 Oct 25. doi: 10.1001/jamaoncol.2018.4514. [Epub ahead of print]

PMID:
30422243
5.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

PMID:
30347289
6.

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.

Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI).

Cancer Immunol Immunother. 2018 Oct 11. doi: 10.1007/s00262-018-2258-1. [Epub ahead of print]

PMID:
30311027
7.

How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies.

Ascierto PA, Marabelle A.

Ann Oncol. 2018 Nov 1;29(11):2157-2160. doi: 10.1093/annonc/mdy420. No abstract available.

PMID:
30307539
8.

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J.

Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423.

PMID:
30295695
9.

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma.

Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, Capone F, Acunzo M, Romano G, Nigita G, Mallardo D, Ragone C, Carriero MV, Budillon A, Botti G, Ascierto PA, Mancini R, Ciliberto G.

Cell Death Differ. 2018 Sep 25. doi: 10.1038/s41418-018-0205-5. [Epub ahead of print]

PMID:
30254376
10.

Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.

Ascierto PA, Flaherty K, Goff S.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):751-758. doi: 10.1200/EDBK_199047. Review.

11.

Immunological effects of BRAF+MEK inhibition.

Ascierto PA, Dummer R.

Oncoimmunology. 2018 Jul 23;7(9):e1468955. doi: 10.1080/2162402X.2018.1468955. eCollection 2018. Review.

PMID:
30228935
12.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
30219628
13.

Anti-PD-1 and PD-L1 antibodies in metastatic melanoma.

Simeone E, Ascierto PA.

Melanoma Manag. 2017 Dec;4(4):175-178. doi: 10.2217/mmt-2017-0018. Epub 2017 Nov 21. No abstract available.

14.

Selecting immuno-oncology-based drug combinations - what should we be considering?

Festino L, Vanella V, Trojaniello C, Ascierto PA.

Expert Rev Clin Pharmacol. 2018 Oct;11(10):971-985. doi: 10.1080/17512433.2018.1518713. Epub 2018 Sep 8. Review.

PMID:
30169990
15.

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA.

Salemi R, Falzone L, Madonna G, Polesel J, Cinà D, Mallardo D, Ascierto PA, Libra M, Candido S.

Front Pharmacol. 2018 Aug 14;9:856. doi: 10.3389/fphar.2018.00856. eCollection 2018.

16.

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT.

J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15.

17.

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.

Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA.

JAMA Oncol. 2018 Oct 1;4(10):1382-1388. doi: 10.1001/jamaoncol.2018.2668.

18.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).

Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M.

J Transl Med. 2018 Jul 21;16(1):207. doi: 10.1186/s12967-018-1568-6.

19.

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.

Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA.

J Immunother Cancer. 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1.

20.

Quality assurance in melanoma care: The EU-MELACARE study.

Sommariva A, Forsea AM, Agius D, Ascierto PA, Bastiaannet E, Borgognoni L, Demetriou A, Garbe C, Gavric Z, Hocevar M, Innos K, Larønningen S, Louwman M, Robsahm TE, Rutkwoski P, van Akkooi A, Zorzi M, Pasquali S, van de Velde C, Rossi CR.

Eur J Surg Oncol. 2018 Nov;44(11):1773-1778. doi: 10.1016/j.ejso.2018.06.020. Epub 2018 Jul 3.

PMID:
30001892
21.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

22.

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.

Gridelli C, Ascierto PA, Grossi F, Baldini E, Favaretto A, Garassino MC, Morabito A, Migliorino MR, Rossi A, de Marinis F.

Curr Clin Pharmacol. 2018;13(2):76-84. doi: 10.2174/1574884713666180711160008.

PMID:
29992894
23.

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.

Fratangelo F, Camerlingo R, Carriero MV, Pirozzi G, Palmieri G, Gentilcore G, Ragone C, Minopoli M, Ascierto PA, Motti ML.

Int J Oncol. 2018 Sep;53(3):1149-1159. doi: 10.3892/ijo.2018.4457. Epub 2018 Jun 27.

24.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J.

Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10.

PMID:
29754777
25.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.

Ascierto PA, Bastholt L, Ferrucci PF, Hansson J, Márquez Rodas I, Payne M, Robert C, Thomas L, Utikal JS, Wolter P, Kudlac A, Tuson H, McKendrick J.

Melanoma Res. 2018 Aug;28(4):333-340. doi: 10.1097/CMR.0000000000000455.

26.

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.

Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Ascierto PA, Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, Osella-Abate S, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI).

Eur J Cancer. 2018 Jul;97:59-61. doi: 10.1016/j.ejca.2018.04.005. Epub 2018 May 7. No abstract available.

PMID:
29743138
27.

Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.

Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P.

Eur J Cancer. 2018 Jul;97:7-15. doi: 10.1016/j.ejca.2018.04.004. Epub 2018 May 4.

PMID:
29734047
28.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.

Cancer Cell. 2018 May 14;33(5):853-861.e4. doi: 10.1016/j.ccell.2018.04.001. Epub 2018 May 3.

PMID:
29731394
29.

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.

Audrito V, Managò A, Zamporlini F, Rulli E, Gaudino F, Madonna G, D'Atri S, Antonini Cappellini GC, Ascierto PA, Massi D, Raffaelli N, Mandalà M, Deaglio S.

Oncotarget. 2018 Apr 10;9(27):18997-19005. doi: 10.18632/oncotarget.24871. eCollection 2018 Apr 10.

30.

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

Ascierto PA, Caracò C, Gershenwald JE, Hamid O, Ross M, Sullivan RJ, Puzanov I.

J Transl Med. 2018 Apr 17;16(1):101. doi: 10.1186/s12967-018-1477-8.

31.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C.

N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

PMID:
29658430
32.

Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.

Capone I, Marchetti P, Ascierto PA, Malorni W, Gabriele L.

Front Immunol. 2018 Mar 21;9:552. doi: 10.3389/fimmu.2018.00552. eCollection 2018.

33.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.

PMID:
29573941
34.

The influence of diet on anti-cancer immune responsiveness.

Soldati L, Di Renzo L, Jirillo E, Ascierto PA, Marincola FM, De Lorenzo A.

J Transl Med. 2018 Mar 20;16(1):75. doi: 10.1186/s12967-018-1448-0. Review.

35.

Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124].

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Giacomo AD, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Apr;93:158. doi: 10.1016/j.ejca.2018.02.001. Epub 2018 Mar 13. No abstract available.

PMID:
29548533
36.

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.

Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.

Front Immunol. 2018 Mar 2;9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018.

37.

Genetic alterations in main candidate genes during melanoma progression.

Sini MC, Doneddu V, Paliogiannis P, Casula M, Colombino M, Manca A, Botti G, Ascierto PA, Lissia A, Cossu A, Palmieri G.

Oncotarget. 2018 Jan 3;9(9):8531-8541. doi: 10.18632/oncotarget.23989. eCollection 2018 Feb 2.

38.

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators.

Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29477665
39.

Adjuvant Therapy in Resected Melanoma.

Weber J, Qureshi A, Ascierto PA.

N Engl J Med. 2018 Feb 15;378(7):680. doi: 10.1056/NEJMc1716071. No abstract available.

PMID:
29446288
40.

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A.

Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488. Epub 2018 Feb 13.

41.

Neoadjuvant therapy in melanoma: the next step?

Ascierto PA, Eggermont AMM.

Lancet Oncol. 2018 Feb;19(2):151-153. doi: 10.1016/S1470-2045(18)30016-0. Epub 2018 Jan 18. No abstract available.

PMID:
29361473
42.

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Mar;91:116-124. doi: 10.1016/j.ejca.2017.12.007. Epub 2018 Jan 19. Erratum in: Eur J Cancer. 2018 Mar 13;:.

43.

What is changing in the adjuvant treatment of melanoma?

Ascierto PA, Palmieri G, Gogas H.

Oncotarget. 2017 Dec 6;8(67):110735-110736. doi: 10.18632/oncotarget.22988. eCollection 2017 Dec 19. No abstract available.

44.

Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma.

Tucci M, Passarelli A, Mannavola F, Stucci LS, Ascierto PA, Capone M, Madonna G, Lopalco P, Silvestris F.

Oncoimmunology. 2017 Nov 6;7(2):e1387706. doi: 10.1080/2162402X.2017.1387706. eCollection 2018.

45.

PD-L1 inhibitors in the pipeline: Promise and progress.

Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA.

Oncoimmunology. 2017 Sep 21;7(1):e1365209. doi: 10.1080/2162402X.2017.1365209. eCollection 2017. Review.

46.

Immune Checkpoint Inhibitors in Melanoma and HIV Infection.

Marra A, Scognamiglio G, Peluso I, Botti G, Fusciello C, Filippelli A, Ascierto PA, Pepe S, Sabbatino F.

Open AIDS J. 2017 Nov 14;11:91-100. doi: 10.2174/1874613601711010091. eCollection 2017. Review.

47.

Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.

Ragone C, Minopoli M, Ingangi V, Botti G, Fratangelo F, Pessi A, Stoppelli MP, Ascierto PA, Ciliberto G, Motti ML, Carriero MV.

J Exp Clin Cancer Res. 2017 Dec 8;36(1):180. doi: 10.1186/s13046-017-0650-x.

48.

A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.

Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H.

Cancer Immunol Res. 2018 Jan;6(1):79-86. doi: 10.1158/2326-6066.CIR-17-0412. Epub 2017 Dec 5.

PMID:
29208646
49.

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.

Morello S, Capone M, Sorrentino C, Giannarelli D, Madonna G, Mallardo D, Grimaldi AM, Pinto A, Ascierto PA.

J Transl Med. 2017 Dec 4;15(1):244. doi: 10.1186/s12967-017-1348-8.

50.

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.

Wongchenko MJ, Ribas A, Dréno B, Ascierto PA, McArthur GA, Gallo JD, Rooney IA, Hsu J, Koeppen H, Yan Y, Larkin J.

Pigment Cell Melanoma Res. 2018 Jul;31(4):516-522. doi: 10.1111/pcmr.12670. Epub 2017 Dec 10.

PMID:
29156488

Supplemental Content

Loading ...
Support Center